97183 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
Sub-classes:DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND ITS ENCODING GENE, RECOMBINANT EXPRESSION VECTOR, NATURAL KILLER CELL, AND APPLICATION
#2MULTISPECIFIC BINDING PROTEINS THAT BIND DECTIN-1 AND TROP-2 AND METHODS OF USE THEREOF
#3ANTIBODIES TARGETING CD3 AND USES THEREOF
#4CD161 BINDING PROTEINS AND RELATED METHODS
#5ANTI-KLRG1 ANTIBODIES
#6CLEC9A BINDING AGENTS
#7Anti-Urokinase-Type Plasminogen Activator Receptor Antibodies and Methods of Use
#8CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
#9BIOACTIVE CONJUGATES, PREPARATION METHOD AND USE THEREOF
#10MODULATION OF DENDRITIC CELL LINEAGES
#11IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE
#12HUMANIZED ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND MIMETICS THEREOF
#13KLRG1 SIGNALLING THERAPY FOR INFECTIOUS DISEASE
#14NKG2D-NKP46 CELL ADAPTER MOLECULE AND USE THEREOF
#15Chimeric Antigen Receptor and Natural Killer Cells Expressing Same
#16USE OF NKG2D-BASED CELL ADAPTER MOLECULE IN REMOVAL OF AGING CELLS
#17Anti-Inflammatory Polypeptides
#18KLRB1 BINDING AGENTS AND METHODS OF USE THEREOF
#19METHODS AND COMPOSITIONS FOR ENHANCED ANTIGEN PRESENTATION IN THE TUMOR MICROENVIRONMENT
#20CD8 BINDING AGENTS
#21CLL-1 TARGETED IMMUNOTHERAPIES
#22ANTI-IL-27 ANTIBODIES AND USES THEREOF
#23IMMUNO-NANOPARTICLES, AND RELATED CELLS, COMPOSITIONS, METHODS AND SYSTEMS
#24MULTISPECIFIC MOLECULES FOR CLEARANCE OF IMMUNOGLOBULINS IN THE TREATMENT OF AUTOANTIBODY-INDUCED DISEASES
#25ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
#26ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF
#27ANTI-GALECTIN 3 ANTIBODIES AND THEIR USE IN EPILEPSY AND RELATED DISEASES
#28MODIFIED ANTI-GALECTIN-9 ANTIBODY AND USES THEREOF
#29ANTI-CD94 ANTIBODY AND USE THEREOF
#30ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3D AND USE THEREOF
#31KLRB1 BINDING AGENTS AND METHODS OF USE THEREOF
#32ADENO-ASSOCIATED VIRUS GENE THERAPY PRODUCTS AND METHODS
#33CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
#34ANTI-ASGR1 POLYPEPTIDES AND METHODS OF USE FOR IMMUNE TOLERANCE
#35CAR T-CELLS COMPRISING AN ANTI CD33, AN ANTI CLL1 AND AT LEAST ONE FURTHER CAR ANTI CD123 AND/OR FTL3
#36ANTAGONIST FOR TREATING MEMBRANOUS NEPHROPATHY AND USE THEREOF
#37METHODS OF DETECTING DDR1 PHOSPHORYLATION
#38TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR
#39ANTIBODIES TO GALECTIN-3 AND METHODS OF USE THEREOF
#40ANTI-BDCA2 ANTIBODY AND USE THEREOF
#41HUMAN ANTI-HUMAN PLA2R ANTIBODY STANDARD SUBSTANCE AND USE THEREOF
#42KLRB1 BINDING AGENTS AND METHODS OF USE THEREOF
#43BINDING AGENTS AND METHODS OF USE THEREOF
#44ANTI-CLL-1 CHIMERIC ANTIGEN RECEPTORS, ENGINEERED CELLS AND RELATED METHODS
#45BISPECIFIC DENDRITIC CELL ENGAGER AND USES THEREOF
#46MULTISPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
#47MULTIPARTITE RECEPTOR AND SIGNALING COMPLEXES
#48NK ENGAGER MOLECULES AND METHODS OF USE THEREOF
#49ANTI-BLOOD DENDRITIC CELL ANTIGEN 2 ANTIBODIES AND USES THEREOF
#50METHODS FOR MODULATING AN IMMUNE RESPONSE TO CANCER OR TUMOR CELLS
#51ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP)
#52NKG2D EXPRESSING CAR-T CELLS
#53PHARMACEUTICAL COMBINATIONS
#54ANTIBODIES TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
#55PHARMACEUTICAL COMPOSITIONS AND DOSAGE REGIMENS FOR CLINICAL USE OF ANTI-BLOOD DENDRITIC CELL ANTIGEN 2 ANTIBODIES
#56TOLERANCE-INDUCING CONSTRUCTS AND COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF IMMUNE DISORDERS
#57EXTRACELLULAR VESICLE COMPOSITES AND THEIR USES IN THE TREATMENT OF LIVER INJURY
#58Anti-Dectin-2 Antibodies
#59KLRB1 BINDING AGENTS AND METHODS OF USE THEREOF
#60ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF
#61CHIMERIC RECEPTORS TARGETING ADGRE2 AND/OR CLEC12A AND USES THEREOF
#62METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKING GALECTIN-3
#63ANTI-CD161 ANTIBODIES AND USES THEREOF
#64CD83 DUAL CAR T CELLS
#65ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF
#66PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS
#67MULTISPECIFIC BINDING PROTEINS THAT BIND DECTIN-1 AND CD20 AND METHODS OF USE THEREOF
#68Anti-GAL3 Antibodies and Compositions
#69Antibody-Drug Conjugates Targeting uPARAP Comprising Exatecan Derivatives
#70MULTI-SPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D, AND CD16, AND METHODS OF USE
#71METHODS OF DEPLETING DISEASE CAUSING AGENTS VIA ANTIBODY TARGETED PHAGOCYTOSIS
#72CD161 BINDING PROTEINS AND RELATED METHODS
#73ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF
#74ANTI-CD94 ANTIBODIES AND METHODS OF USE THEREOF
#75BISPECIFIC DENDRITIC CELL ENGAGER AND USES THEREOF
#76NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
#77CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER
#78ANTI-CLECL1 ANTIBODIES FOR TREATMENT AND PROGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA AND OTHER DISEASES
#79ANTI-GAL3 ANTIBODIES AND METHODS OF USE
#80ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF
#81Anti-CD161 antibodies and uses thereof
#82MODIFIED A1-A2 DOMAINS OF NON-NATURAL NKG2D LIGANDS THAT BIND NON-NATURAL NKG2D RECEPTORS
#83METHODS OF TREATING DISORDERS ASSOCIATED WITH EXCESS OR UNWANTED KILLER CELL LECTIN-LIKE RECEPTOR SUBFAMILY G MEMBER 1 (KLRG1) EXPRESSING T CELLS WITH KLRG1 DEPLETING ANTIBODIES
#84ANTI-CD94 ANTIBODY AND CHIMERIC ANTIGEN RECEPTOR AND METHODS OF USE THEREOF
#85KILLER CELL LECTIN-LIKE RECEPTOR SUBFAMILY G MEMBER 1 (KLRG1) DEPLETING ANTIBODIES
#86ANTI-CD33 ANTIBODIES AND USES THEREOF
#87ANTIBODIES AGAINST CLL1 AND CONSTRUCTS THEREOF
#88SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING
#89CLEC9A BINDING AGENTS AND USE THEREOF
#90GALECTIN-10 ANTIBODIES
#91NEBULIZATION OF FAB FRAGMENTS
#92CD33-Binding Polypeptides and Uses Thereof
#93Intestinal Tumor Suppressor, PGE2 Production Inhibitor, and IL-22BP Production Promoter
#94ASGR INHIBITORS
#95TARGETED REGULATION OF PLATELET AND MEGAKARYOCYTE ACTIVATION BY HETERORECEPTOR CO-CLUSTERING
#96ANTIBODY-DRUG CONJUGATE
#97Identification of CLEC-1 Ligand and Uses Thereof
#98METHODS OF PREVENTING PROTEIN AGGREGATION
#99BISPECIFIC IGG ANTIBODIES AS T CELL ENGAGERS
#100UNIVERSAL SARBECOVIRUS VACCINES
#101ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR
#102ANTI-IgE ANTIBODIES
#103CLEC12a Binding Polypeptides and Uses Thereof
#104Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#105MOLECULES THAT BIND TO CD94/NKG2A HETERODIMER POLYPEPTIDES
#106Novel Immune Cell Engagers For Immunotherapy
#107METHODS FOR PROMOTING T CELLS RESPONSE
#108CHIMERIC ANTIGEN RECEPTOR AND CELL INCLUDING CHIMERIC ANTIGEN RECEPTOR
#109MULTISPECIFIC ANTIBODIES FOR USE IN TREATING DISEASES
#110DUPLEXBODIES
#111COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY
#112FORMULATIONS OF ANTIBODY MOLECULES TO DENGUE VIRUS
#113Universal Receptor Immune Cell Therapy
#114CLEC9A BINDING AGENTS AND USE THEREOF
#115PROTEINS BINDING NKG2D, CD16 AND BAFF-R
#116MULTIVALENT ANTIBODY
#117DIMERIC PROTEIN COMPLEXES AND USES THEREOF
#118METHODS OF TREATING EYE DISEASE
#119MULTIVALENT ANTIBODY
#120MODIFIED IMMUNE CELLS EXPRESSING TLR RECEPTORS
#121TISSUE-DIRECTED ANTIBODIES AND METHODS OF USING THE SAME
#122ENGINEERED T CELL RECEPTORS FUSED TO BINDING DOMAINS FROM ANTIBODIES
#123DEPLETING MONOCLONAL ANTIBODIES AGAINST NATURAL KILLER CELLS
#124HUMANIZED ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND MIMETICS THEREOF
#125ANTI-CD72 NANOBODIES FOR IMMUNOTHERAPY
#126ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF IN THE TREATMENT OF OCULAR MELANOMA
#127ANTI-CD72 CHIMERIC RECEPTORS AND USES THEREOF
#128Anti-CD161 antibodies and uses thereof
#129TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOF
#130PROTEINS BINDING NKG2D, CD16 AND BAFF-R
#131ANTI-DDR2 ANTIBODIES AND USES THEREOF
#132MULTI-SPECIFIC ANTIBODY CONSTRUCTS AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ED)
#133CLEC12AXCD3 BISPECIFIC ANTIBODIES AND METHODS FOR THE TREATMENT OF DISEASE
#134DEPLETION OF ACTIVATED HEPATIC STELLATE CELLS (HSCS) AND USES THEREOF
#135PHARMACEUTICAL COMBINATION COMPRISING AN ANTI-CD205 ANTIBODY AND AN IMMUNE CHECKPOINT INHIBITOR
#136COMPOSITIONS AND METHODS FOR T-CELL AND CYTOKINE ACTIVATION
#137NOVEL PROTEIN SPECIFICALLY BINDING TO CALRETICULIN AND HAVING HUMAN FIBRONECTIN DOMAIN III SCAFFOLD AND USE THEREOF
#138CO-STIMULATORY MULTISPECIFIC ANTIBODIES
#139Methods and Compositions for Treating Mucus Obstruction in Severe Asthma
#140GALECTIN-1-SPECIFIC MONOVALENT ANTIBODIES AND USES THEREOF
#141ANTI-NKG2D ANTIBODIES AND USES THEREOF
#142PROTEINS BINDING HER2, NKG2D AND CD16
#143CD94 ENGINEERED CELL AND COMPOSITION THEREOF
#144MUTATED FERRITIN PROTEIN
#145RADIOIMMUNOCONJUGATES DIRECTED TO NKG2D LIGANDS FOR THE TREATMENT OF CANCER
#146ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF
#147HYPERGLYCOSYLATED BINDING POLYPEPTIDES
#148Bispecific Molecules and Related Compositions and Methods
#149COMBINATION OF ANTI-GALECTIN-9 ANTIBODIES AND CHEMOTHERAPEUTICS FOR USE IN CANCER THERAPY
#150MATERIALS AND METHODS FOR IMMUNE EFFECTOR CELLS REDIRECTION
#151CHIMERIC CYTOKINE RECEPTORS AND USES THEREOF IN CELLULAR THERAPIES
#152DIAGNOSIS AND TREATMENT OF MYELOID DISORDERS AND ACUTE LEUKEMIAS USING NOVEL TUMOR SPECIFIC ANTIGENS
#153ANTI-KLRG1 ANTIBODIES
#154MOLECULES THAT BIND TO CD66e POLYPEPTIDES
#155MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN FOR ACTIVATION OF NATURAL KILLER CELLS AND THERAPEUTIC USES THEREOF TO TREAT CANCER
#156ANTI-GAL3 ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF
#157NATURAL KILLER CELL ANTIBODIES WITH INCREASED ADCC ACTIVITY
#158GAMMA DELTA T-CELL COSTIMULATION
#159CHLAMYDIA VACCINE BASED ON TARGETING MOMP VS4 ANTIGEN TO ANTIGEN PRESENTING CELLS
#160CD94 ENGINEERED CELL AND COMPOSITION THEREOF
#161PROTEINS BINDING NKG2D, CD16, AND CEACAM5
#162NUCLEIC ACID SEQUENCING USING AFFINITY REAGENTS
#163SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES
#164PROTEINS BINDING NKG2D, CD16 AND FLT3
#165CLEC12A ANTIBODY FRAGMENT SEQUENCES AND METHODS
#166ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF
#167HUMAN CD3 BINDING ANTIBODY
#168POLYPEPTIDES AND THEIR USE IN TREATMENT OF DISEASE
#169DEPLETION AND INHIBITION OF PLASMACYTOID DENDRITIC CELLS
#170LDL RECEPTOR-DIRECTED BISPECIFIC BINDING AGENT-LIGAND FUSIONS FOR THE DEGRADATION OF TARGET PROTEINS
#171SURFACE COATING PPSU NANOPARTICLES FOR THERAPEUTIC MODULATION OF MAST CELLS
#172METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION
#173Antibody-drug conjugate
#174Antibody variable domains targeting the NKG2D receptor
#175Antibody variable domains targeting the NKG2D receptor
#176CHIMERIC RECEPTOR CONSTRUCTS FOR NK CELLS
#177Antibody variable domains targeting the NKG2D receptor
#178Antibodies binding to NKG2D
#179SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES
#180ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF
#181T CELL AND ANTIGEN-PRESENTING CELL ENGAGERS AND USES THEREOF
#182GALECTIN-10 ANTIBODIES
#183ANTIBODIES TO GALECTIN-3 AND METHODS OF USE THEREOF
#184CAR Cells and Polyspecific Binding Molecules for Treating Solid Tumor
#185METHODS OF TREATING CUTANEOUS LUPUS ERYTHEMATOSUS AND SYSTEMIC LUPUS ERYTHEMATOSUS
#186METHODS AND COMPOSITIONS FOR DEPLETING NATURAL KILLER CELLS AND USES THEREOF IN CELLULAR THERAPIES
#187ANTIBODIES CONJUGATED OR FUSED TO THE RECEPTOR-BINDING DOMAIN OF THE SARS-COV-2 SPIKE PROTEIN AND USES THEREOF FOR VACCINE PURPOSES
#188ANTIBODIES THAT BIND TO C-TYPE LECTIN DOMAIN FAMILY 2 MEMBER D (CLEC2D)
#189Preparation of therapeutic exosomes using membrane proteins
#190METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND HER2
#191SELECTIVE ELIMINATION OF EROSIVE CELLS
#192Anti-Dectin-2 Antibodies
#193ENGINEERED IPSC AND IMMUNE EFFECTOR CELLS FOR HETEROGENOUS TUMOR CONTROL
#194MULTISPECIFIC BINDING PROTEINS TARGETING CEA
#195CLEC9A antibodies
#196METHODS FOR CONCENTRATING PROTEINS
#197COMBINATION THERAPY FOR TREATING COLORECTAL CANCER
#198PROTEINS BINDING NKG2D, CD16 AND NECTIN4
#199DOWNREGULATION OF MEMBRANE-BOUND PROTEINS BY RECEPTOR TAC TECHNOLOGY
#200PHARMACEUTICAL FORMULATION
#201TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING IL-15/IL-15RA AND NKG2D ANTIGEN BINDING DOMAINS
#202CHIMERIC RECEPTORS AND METHODS OF USE THEREOF
#203METHODS AND COMPOSITIONS FOR TREATING SYSTEMIC MASTOCYTOSIS
#204METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASES OR CONDITIONS RELATED TO INNATE LYMPHOID CELLS
#205ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENT THEREOF
#206CAR T-CELLS COMPRISING AN ANTI CD33, AN ANTI CLL1 AND AT LEAST ONE FURTHER CAR ANTI CD123 AND/OR FTL3
#207CD33-binding polypeptides and uses thereof
#208Glycan-dependent Immunotherapeutic Molecules
#209COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
#210Galectin-9 Specific Binding Agents for Use in Treating Cancer
#211Anti-Inflammatory Polypeptides
#212SIGLEC-6-BINDING POLYPEPTIDES
#213METHODS OF TREATING OR INHIBITING CARDIOVASCULAR DISEASES
#214RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY
#215DUAL CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING CCD99- AND CLEC12A-EXPRESSING CANCERS
#216CIS-Binding Siglec Agonists and Related Compositions And Methods
#217PROTEINS BINDING NKG2D, CD16 AND EGFR
#218PPHARMACEUTICAL FORMULATIONS AND THERAPEUTIC USES OF MULTI-SPECIFIC BINDING PROTEINS THAT BIND EGFR, NKG2D, AND CD16
#219Glycome factors driving melanoma progression
#220COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
#221METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES
#222Antibodies Targeting CLEC12A and Use Thereof
#223SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) POLYPEPTIDES AND USES THEREOF FOR VACCINE PURPOSES
#224RECOMBINANT POLYPEPTIDES FOR PROGRAMMING EXTRACELLULAR VESICLES
#225NANO ANTIBODY AND USE THEREOF
#226EXTRACELLULAR VESICLES TARGETING DENDRITIC CELLS AND USES THEREOF
#227FULLY HUMAN ANTI-HUMAN CD22 CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF
#228Neoepitope immunotherapy with APC targeting unit
#229ENGINEERED REGULATORY T CELL
#230Site-specific antibody-drug conjugates by ADP-ribosyl cyclases
#231MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF
#232GUIDANCE AND NAVIGATION CONTROL (GNC) ANTIBODY-LIKE PROTEINSAND METHODS OF MAKING AND USING THEREOF
#233ANTI-CLEC12A ANTIBODIES AND USES THEREOF
#234THERAPEUTIC INTERFERON ALPHA 1 PROTEINS
#235MULTIFUNCTIONAL MOLECULES THAT BIND TO CD33 AND USES THEREOF
#236ANTIBODIES THAT DISRUPT THE INTERACTION OF GAL3 AND INSULIN RECEPTOR OR INTEGRINS AND METHODS OF USE THEREOF
#237ANTIBODY MOLECULES WHICH BIND CD22
#238ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF
#239ANTI-GALECTIN-9 ANTIBODY AND USES THEREOF
#240DC-SIGN ANTIBODY DRUG CONJUGATES
#241ANTI-GAL3 ANTIBODIES AND METHODS OF USE
#242METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#243Heterodimeric Fc-fused proteins
#244Chimeric Antigen Receptor and Natural Killer Cells Expressing Same
#245INFECTIOUS DISEASE VACCINES
#246ANTI-SIGLEC-9 ANTIBODY MOLECULES
#247INSERTABLE VARIABLE FRAGMENTS OF ANTIBODIES AND MODIFIED A1-A2 DOMAINS OF NKG2D LIGANDS
#248CYS80 CONJUGATED IMMUNOGLOBULINS
#249ANTI-GAL3 ANTIBODIES AND METHODS OF USE FOR INSULIN RESISTANCE
#250MULTITARGETING ANTIGEN-BINDING MOLECULES FOR USE IN PROLIFERATIVE DISEASES
#251ANTI-IDIOTYPIC ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
#252ANTI-SIGLEC-9 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFLAMMATORY PHENOTYPES AND USES THEREOF
#253ANTI-CLL1 ANTIBODY AND USE THEREOF
#254TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF
#255ANTI-GAL3 ANTIBODIES AND USES THEREOF
#256CONJUGATED CHIMERIC PROTEINS
#257CHIMERIC RECEPTORS TARGETING ADGRE2 AND/OR CLEC12A AND USES THEREOF
#258CLEC9A BINDING AGENTS
#259CHIMERIC ANTIGEN RECEPTOR TARGETING CLL1 AND USE THEREOF
#260COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF
#261NOVEL RECEPTORS HAVING A FIBRONECTIN REPEAT FOR LIGAND-DEPENDENT TRANSCRIPTIONAL REGULATION
#262COMBINED CANCER THERAPY OF ANTI-GALECTIN-9 ANTIBODIES AND CHEMOTHERAPEUTICS
#263NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
#264CLL-1 TARGETED IMMUNOTHERAPIES
#265B CELL TARGETED PARALLEL CAR (pCAR) THERAPEUTIC AGENTS
#266PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY
#267Method of promoting a t-cell response or treating cancer by administering an antagonist to human c-type lectin-like receptor-1 (CLEC-1)
#268BISPECIFIC ANTIBODY CAR CELL IMMUNOTHERAPY
#269ANTI-IL-27 ANTIBODIES AND USES THEREOF
#270IMMUNOTHERAPY TARGETING CELL SURFACE MARKER CD72 FOR THE TREATMENT OF B-CELL MALIGNANCIES
#271ANTI-CD33 ANTIBODIES FOR TREATING CANCER
#272TARGETING GALECTIN-9 AS A THERAPEUTIC STRATEGY FOR T-CELL EXHAUSTION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
#273Anti-IgE antibodies
#274METHODS AND COMPOSITIONS FOR TREATING A DISEASE OR DISORDER
#275ACTIVATING ANTI-GAL9 BINDING MOLECULES
#276TOXOPLASMA PLATFORM FOR TREATING CANCER
#277ANTI-GAL9 IMMUNE-INHIBITING BINDING MOLECULES
#278Anti-TEM1 antibodies and antigen-binding portions thereof
#279Antibody specific for CD22 and methods of use thereof
#280Cancer Treatment by Targeting Plexins in the Immune Compartment
#281ENDOSIALIN-BINDING ANTIBODY
#282ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
#283COMPOSITIONS AND METHODS FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINS
#284Synthetic immune receptors and methods of use thereof
#285PHARMACEUTICAL FORMULATIONS AND DOSAGE REGIMENS FOR MULTI-SPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D, AND CD16 FOR CANCER TREATMENT
#286COMPOSITIONS AND METHODS FOR INHIBITING CANCER STEM CELLS
#287ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
#288METHODS OF REDUCING LARGE GRANULAR LYMPHOCYTE AND NATURAL KILLER CELL LEVELS
#289ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
#290CD8 BINDING AGENTS
#291METHODS OF DEPLETING DISEASE CAUSING AGENTS VIA ANTIBODY TARGETED PHAGOCYTOSIS
#292Inhibitory Immune Receptor Inhibition Methods and Compositions
#293ANTI BDCA-2 ANTIBODIES
#294Anti-Dectin-2 antibodies
#295PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#296Anti-Dectin-1 antibodies and methods of use thereof
#297Anti-CD94 antibodies and methods of use thereof
#298Compositions and Methods for Preventing the Interaction Between SARS-COV-2 and L-Sign
#299Site-specific glycoengineering of targeting moieties
#300Proteins binding NKG2D, CD16 and CLEC12A